Targeting CD43 optimizes cancer immunotherapy through reinvigorating anti-tumor immune response in colorectal cancer

We report a novel immune molecule, CD43, that can regulate the tumor immune microenvironment (TIME) and serves as a promising target for CRC immunotherapy. The correlation of CD43 expression with CRC patient prognosis was revealed by public data analysis. CD43 KO CRC cell lines were generated by CRISPR-CAS9 technology, and a syngenetic murine CRC model was established to investigate the in vivo function of CD43.To elucidate the TIME more precisely, tumors were harvested at Day 21 postinoculation in vivo, and single-cell suspensions of tumor tissues were generated for transcriptome sequencing. Overall design: Comparative gene expression profiling analysis of RNA-seq data for Vec-MC38 and CD43-KO MC38 tumors.